Minocycline enhances MPTP toxicity to dopaminergic neurons

Journal of Neuroscience Research

Volumn 74, Issue 2, 2003, Pages 278-285

  Yang, Lichuan ^a   Sugama, Shuei ^a   Chirichigno, Jason W ^a   Gregorio, Jason ^a   Lorenzl, Stefan ^a   Shin, Dong H ^a   Browne, Susan E ^a   Shimizu, Yoshinori ^a   Joh, Tong H ^a   Beal, M Flint ^a   Albers, David S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Doxycycline; Inflammation; Parkinson's disease; Tetracycline; Vesicles

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPHETAMINE; DOXYCYCLINE; MINOCYCLINE; OXIDOPAMINE; TETRACYCLINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CELL ACTIVATION; CELL COUNT; CELL LOSS; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUNTINGTON CHOREA; INHIBITION KINETICS; LIFESPAN; MALE; MICROGLIA; MOUSE; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; GLIOSIS; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MINOCYCLINE; NEOSTRIATUM; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; SYNAPTIC VESICLES; TETRACYCLINE;

EID: 0141593395     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10709     Document Type: Article

References (43)

1. Albers DS, Zeevalk GD, Sonsalla PK. 1996. Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res 718:217-220.
2. Amin AR, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. 1996. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 93:14014-14019.
3. Berman SB, Hastings TG. 1999. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 73:1127-1137.
4. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, DiMonte D. 2002. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 83:167-175.
5. Chen MO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801.
6. Chiba K, Trevor A, Castagnoli N Jr. 1984. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574-578.
7. Coggeshall R. 1992. A consideration of neural counting methods. Trends Neurosci 15:9-12.
8. DeGiorgio LA, Dibinis C, Milner TA, Saji M, Volpe BT. 1998. Histological and temporal characteristics of nigral transneuronal degeneration after striatal injury. Brain Res 795:1-9.
9. Del Zompo M, Piccardi MP, Ruiu S, Quartu M, Gessa GL, Vaccari A. 1993. Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br J Pharmacol 109:411-414.
10. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's Disease. Proc Natl Acad Sci USA 98:14669-14674.
11. Gainetdinov RR, Fumagalli F, Wang YM, Jones SR, Levey AI, Miller GW, Caron MG. 1998. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70:1973-1978.
12. German DC, Liang CL, Manaye KF, Lane K, Sonsalla PK. 2000. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 101:1063-1069.
13. German DC, Manaye KE. 1993. Midbrain dopaminergic neurons (Nuclei A9 and A10). J Comp Neurol 331:297-309.
14. Ghulam N, Sager T, Laursen H, Vaudano E. 2001. Minocycline reduces microglia activation in the chronic MPTP mouse model of Parkinson's Disease. Soc Neurosci 27:887-888.
15. Gundersen HJ. 1992. Stereology: the fast lane between neuroanatomy and brain function-or still only a tightrope? Acta Neurol Scand 137:8-13.
16. He Y, Appel S, Le W. 2001. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187-193.
17. Heikkila RE, Hess A, Duvoisin RC. 1984. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Science 224:1451-1453.
18. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. 1985. Parkinsonism-induced neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177.
19. Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW, Burke WJ. 2001. Selective dopaminergic vulnerability: 3,4-dihydroxy-phenylacetaldehyde targets mitochondria. Free Rad Biol Med 30:924-931.
20. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowska A, Czlonkowska A. 1999. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50-61.
21. Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
22. Liberatore GT, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med 5:1403-1409.
23. Liu Y, Peter D, Roghani A, Schuldiner S, Prive GG, Eisenberg D, Brecha N, Edwards RH. 1992. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70:539-551.
24. Matthews RT, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF. 1999. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142-149.
25. McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG. 1993. Microglia in degenerative neurological disease. Glia 7:84-92.
26. Nagatsu T, Mogi M, Ichinose H, Togari A. 2000. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 60:277-920.
27. Nicklas WJ, Vyas I, Heikkila RE. 1985. Inhibition of NADH-linked oxidation by brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36:2503-2508.
28. Rousselet E, Callebert J, Parain K, Joubert C, Hunot S, Hartmann A, Jacque C, Perez-Diaz F, Cohen-Salmon C, Launay J-M, Hirsch EC. 2002. Role of TNFalpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp Neurol 17:183-192.
29. Sonsalla PK, Giovanni A, Sieber BA, Donne KD, Manzino L. 1992. Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Ann N Y Acad Sci 648:229-238.
30. Staal RG, Hogan KA, Liang C-L, German DC, Sonsalla PK. 2000. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 293:329-335.
31. Staal RG, Sonsalla PK. 2000. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridium in vivo in rat striata. J Pharmacol Exp Ther 293:336-342.
32. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR. 1997. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943.
33. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. 2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21:2580-2588.
34. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr. 2001. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-7819.
35. Volpe BT, Blau AD, Wessel TC, Saji M. 1995. Delayed histopathological neuronal damage in the substantia nigra compacta (nucleus A9) after transient forebrain ischaemia. Neurobiol Dis 2:119-127.
36. Volpe BT, Wildmann J, Altar CA. 1998. Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience 83:741-748.
37. Weiser M, Baker H, Wessel TC, Joh TH. 1993. Differential spatial and temporal gene expression in response to axotomy and deafferentation following transection of the medial forebrain bundle. J Neurosci 13:3472-3484.
38. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi D-K, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 22:1763-1771.
39. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600-606.
40. Yang L, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney JB Jr, Hyman BT, Beal MF. 1998. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 18:8145-8152.
41. Yrjanheikki J, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. 1999. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13496-13500.
42. Yrjanheikki J, Pellikka M, Hokfelt T, Koistinaho J. 1998. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95:15769-15774.
43. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM. 2002. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74-78.